双歧杆菌三联活菌肠溶胶囊联合熊去氧胆酸治疗原发性胆汁性胆管炎患者效果观察

Effects of bifidobacterium triplex live enteric capsule combined with ursodeoxycholic acid on patients with primary biliary cholangitis

目的:探讨双歧杆菌三联活菌肠溶胶囊联合熊去氧胆酸治疗原发性胆汁性胆管炎(PBC)患者的效果。方法:选取160例PBC患者,按照随机数字表法分为两组,每组各80例。对照组给予熊去氧胆酸治疗,实验组给予双歧杆菌三联活菌肠溶胶囊联合熊去氧胆酸治疗。对比两组治疗前、治疗6个月后肝纤维化指标[IV型胶原(IV-C)、血清Ⅲ型前胶原(PCⅢ)、透明质酸酶(HA)]、肠道菌群[酵母样真菌、肠杆菌、大肠埃希菌]、炎性因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)]水平。结果:治疗6个月后,实验组血清IV-C、PCⅢ、HA水平低于对照组(P<0.05);治疗6个月后,实验组酵母样真菌、肠杆菌、大肠埃希菌水平低于对照组(P<0.05);治疗6个月后,实验组血清TNF-α、IL-6水平低于对照组(P<0.05)。结论:双歧杆菌三联活菌肠溶胶囊联合熊去氧胆酸治疗PBC患者能有效缓解肝纤维化程度,调节肠道菌群及炎性因子水平。

Objective: To investigate the efficacy of bifidobacterium triplex live enteric capsule combined with ursodeoxycholic acid in the treatment of patients with primary biliary cholangitis(PBC). Methods: A total of 160 PBC patients were randomized into 2 groups, each with 80 cases. The control group were treated with ursodeoxycholic acid, while the experimental group were treated with bifidobacterium triplex enteric-dissolved capsules combined with ursodeoxycholic acid. The liver fibrosis indexes[type IV collagen(IV-C), serum procollagen type Ⅲ(PCⅢ), hyaluronidase(HA)], intestinal flora(fungal yeast, enteric bacilli, escherichia coli), and inflammatory factor level[tumor necrosis factor alpha(TNF-a), interleukin 6(IL-6)]were compared between both groups before treatment and 6 months after treatment. Results: After 6 months of treatment, the levels of IV-C, PCⅢ and HA in the experimental group were lower than those in the control group(P<0.05);the levels of yeast-like fungi, enterobacteria and escherichia coli in the experimental group were lower than those in the control group(P<0.05);the serum levels of TNF-α and IL-6 in the experimental group were lower than those in the control group(P<0.05). Conclusion: Bifidobacterium triplex live enteric capsule combined with ursodeoxycholic acid can effectively alleviate the degree of liver fibrosis, regulate the level of intestinal flora and inflammatory factors in patients with PBC.